Characterization of killer cells in ovarian cancer
Research type
Research Study
Full title
Characterization of killer cells in ovarian cancer
IRAS ID
312429
Contact name
Francesco Colucci
Contact email
Sponsor organisation
Unversity of Cambridge
Clinicaltrials.gov Identifier
201-15, Ethical permit from the regional ethical committee, Gothenburg, Sweden
Duration of Study in the UK
2 years, 11 months, 28 days
Research summary
Ovarian cancer is the most lethal of gynecological cancers, with a poor prognosis for patients that are diagnosed in late stages due to lack of efficient therapies. Thus, there is a big demand to develop new therapies to treat ovarian cancer. In this study, we want to investigate how certain immune cells with an inherent capacity to kill transformed cells are regulated in ovarian cancer. Moreover, we will investigate if a specific type of drug that interferes with the inhibitory input that killer cells may receive from tumor cells, called checkpoint blockade treatment, may potentiate the killer cells to better eradicate tumor cells. The overall aim is to get one step closer to the use of immunotherapy in ovarian cancer, leading to prolonged survival for these patients.
This is a collaborative project between University of Gothenburg, Sweden, and University of Cambridge, UK. Samples from patients with ovarian cancer are collected at the Sahlgrenska hospital, Gothenburg, Sweden, and shipped to Cambridge for further analysis.
REC name
London - London Bridge Research Ethics Committee
REC reference
22/PR/0287
Date of REC Opinion
8 Mar 2022
REC opinion
Favourable Opinion